BeiGene's BTK inhibitor fails to beat market leader Imbruvica in key head-to-head study
BeiGene’s quest to develop a superior BTK inhibitor hit a major roadblock on Monday as the company conceded that the drug failed a keenly anticipated head-to-head trial testing its recently approved drug, Brukinsa, against the market-leading Imbruvica.
The results amount to a serious setback for China’s BeiGene that is hoping to position Brukinsa, known chemically as zanubrutinib, as the best-in-class therapy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.